JAM3 and ovarian carcinoma: Moreover, a junctional adhesion molecule 3 (JAM3)-driven NRF2–FSP1 signaling axis has recently emerged as a critical mediator of dual resistance to cisplatin and ferroptosis, highlighting the potential of targeting FSP1 or its upstream regulators to effectively overcome multidrug resistance in ovarian cancer [25,92].